MX2012013589A - Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). - Google Patents
Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).Info
- Publication number
- MX2012013589A MX2012013589A MX2012013589A MX2012013589A MX2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A
- Authority
- MX
- Mexico
- Prior art keywords
- jnk
- inhibitors
- amino
- pyrimidine derivatives
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la Fórmula I o sales farmacéuticamente aceptable de los mismos, en donde R5 es un grupo de la Fórmula (a) o (b); y en donde m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8, y R9 son como se definió aquí. Los compuestos y composiciones descritos aquí son útiles para modular la actividad de JNK y tratar enfermedades asociadas con actividad de JNK.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35165210P | 2010-06-04 | 2010-06-04 | |
PCT/EP2011/059005 WO2011151358A1 (en) | 2010-06-04 | 2011-06-01 | 2 -amino- pyrimidine derivatives useful as inhibitors of jnk |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012013589A true MX2012013589A (es) | 2012-12-17 |
Family
ID=44201987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013589A MX2012013589A (es) | 2010-06-04 | 2011-06-01 | Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). |
Country Status (12)
Country | Link |
---|---|
US (1) | US8642601B2 (es) |
EP (1) | EP2576537B1 (es) |
JP (1) | JP5916719B2 (es) |
KR (1) | KR101800916B1 (es) |
CN (1) | CN102918035B (es) |
BR (1) | BR112012030931A2 (es) |
CA (1) | CA2799328C (es) |
ES (1) | ES2567828T3 (es) |
HK (1) | HK1177931A1 (es) |
MX (1) | MX2012013589A (es) |
RU (1) | RU2572247C2 (es) |
WO (1) | WO2011151358A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104036185B (zh) * | 2014-06-23 | 2017-04-12 | 常熟理工学院 | 基于虚拟化的宏内核操作***载入模块权能隔离方法 |
WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
CN113956240B (zh) * | 2021-11-03 | 2023-02-14 | 陕西师范大学 | 一类嘧啶衍生物及其制备抗肿瘤药物的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA78035C2 (en) * | 2002-04-25 | 2007-02-15 | Applied Research Systems | Piperazine benzothiazole for treatment of cerebral ischemic disorders or cns disorders |
WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
BRPI0717035B8 (pt) * | 2006-09-08 | 2021-05-25 | Hoffmann La Roche | moduladores de benzotriazol cinase |
RU2493155C2 (ru) * | 2006-12-08 | 2013-09-20 | Ф.Хоффманн-Ля Рош Аг | Замещенные пиримидины и их применение в качестве модуляторов jnk |
JP5329648B2 (ja) * | 2008-05-16 | 2013-10-30 | エフ.ホフマン−ラ ロシュ アーゲー | Jnkの阻害剤 |
-
2011
- 2011-06-01 MX MX2012013589A patent/MX2012013589A/es active IP Right Grant
- 2011-06-01 CA CA2799328A patent/CA2799328C/en not_active Expired - Fee Related
- 2011-06-01 JP JP2013512882A patent/JP5916719B2/ja not_active Expired - Fee Related
- 2011-06-01 ES ES11723059.9T patent/ES2567828T3/es active Active
- 2011-06-01 RU RU2012155143/04A patent/RU2572247C2/ru not_active IP Right Cessation
- 2011-06-01 BR BR112012030931A patent/BR112012030931A2/pt not_active IP Right Cessation
- 2011-06-01 EP EP11723059.9A patent/EP2576537B1/en not_active Not-in-force
- 2011-06-01 WO PCT/EP2011/059005 patent/WO2011151358A1/en active Application Filing
- 2011-06-01 CN CN201180027084.2A patent/CN102918035B/zh not_active Expired - Fee Related
- 2011-06-01 KR KR1020137000098A patent/KR101800916B1/ko active IP Right Grant
- 2011-06-02 US US13/151,326 patent/US8642601B2/en not_active Expired - Fee Related
-
2013
- 2013-04-24 HK HK13104949.9A patent/HK1177931A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2012155143A (ru) | 2014-07-20 |
EP2576537A1 (en) | 2013-04-10 |
CA2799328A1 (en) | 2011-12-08 |
CN102918035B (zh) | 2015-05-27 |
HK1177931A1 (en) | 2013-08-30 |
CN102918035A (zh) | 2013-02-06 |
CA2799328C (en) | 2018-02-20 |
KR101800916B1 (ko) | 2017-11-23 |
US20110301171A1 (en) | 2011-12-08 |
RU2572247C2 (ru) | 2016-01-10 |
JP2013527215A (ja) | 2013-06-27 |
BR112012030931A2 (pt) | 2016-11-08 |
WO2011151358A1 (en) | 2011-12-08 |
ES2567828T3 (es) | 2016-04-26 |
EP2576537B1 (en) | 2016-03-16 |
US8642601B2 (en) | 2014-02-04 |
JP5916719B2 (ja) | 2016-05-11 |
KR20130085406A (ko) | 2013-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501192B1 (en) | Certain amino-pyridazines, compositions thereof, and methods of their use | |
TW201204363A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
PH12016501204A1 (en) | Syk inhibitors | |
MY162535A (en) | Inhibitors of arginase and their therapeutic applications | |
MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
TN2011000400A1 (en) | Inhibitors of beta-secretase | |
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
PH12014501417A1 (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
MY165238A (en) | Substituted pyrrolidine-2-carboxamides | |
MY184306A (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
MX2017000330A (es) | Derivado de piridona que tiene un grupo tetrahidropiranilmetilo. | |
IN2014DN07509A (es) | ||
MY165918A (en) | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | |
MX344911B (es) | Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos. | |
MX364400B (es) | Compuestos de tetraciclina. | |
MX355561B (es) | Proceso para hacer inhibidores de girasa y topoisomerasa iv. | |
MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
MX2012013589A (es) | Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). | |
MX345264B (es) | Derivado de azol. | |
IN2014CN04922A (es) | ||
MX2013005825A (es) | Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion. | |
MX358151B (es) | Derivado de sitaxentan. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |